14P - Tumor microcirculation based biomarker discovery strategy for non-small cell lung cancer (NSCLC)

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Thoracic Malignancies
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Donats Breiva
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors D. Breiva1, I. Tracums1, I. Jaunalksne2, D. Krievins3, A. Bistrova1, A. Spaks1
  • 1Thoracic Surgery, Pauls Stradins Clinical University Hospital, LV-1002 - Riga/LV
  • 2Clinical Immunology, Pauls Stradins Clinical University Hospital, LV-1002 - Riga/LV
  • 3Vascular Surgery, Pauls Stradins Clinical University Hospital, LV-1002 - Riga/LV



Measuring levels of ligands in peripheral blood representing systemic circulation and in blood isolated from tumour vascular bed accompanied by evaluation of binding receptor expression in tumour tissue gives insight into cancerogenesis. We have incorporated this research strategy into surgical practice to investigate the role of CXC chemokines as potential biomarkers of lung cancer.


The study recruited 40 patients (mean age 62±10.4) with primary NSCLC ranging from stage IA to IIB undergoing anatomical pulmonary resection between June 2010 and October 2014. Blood samples from peripheral vein and from pulmonary vein draining tumour vascular bed were collected at the time of surgery. Levels of CXC chemokine ligands (CXCL) potentially involved in cancerogenesis – CXCL1, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11 and CXCL12 were measured using ELISA. CXCL gradients were calculated. Corresponding CXC chemokine receptor (CXCR) expression – CXCR1, CXCR2, CXCR3 and CXCR4 was evaluated in resected tumour by immunohistochemistry and analysed semi-quantitatively (expression intensity scale 0–3). Prognostic value of CXCL levels and CXCR expression was assessed evaluating relapse time. Paired two-tailed t-test was used to compare CXCL levels and Pearson test was used to assess statistical relationship between CXCL levels and CXCR expression.


Statistically significant difference between circulating CXC levels was found for CXCL4 (p 


Our approach has facilitated identifying chemokine ligands and receptors potentially involved in NSCLC tumour metabolism and improved understanding of a complex and variable background of proteomic profile in lung cancer leading to biomarker discovery.

Clinical trial identification

Legal entity responsible for the study

Pauls Stradins Clinical University Hospital


Pauls Stradins Clinical University Hospital


All authors have declared no conflicts of interest.